Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Tumors × cemiplimab × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 20 Skin Neoplasms 7 Melanoma 7 Lung Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 4 Neoplasm Metastasis 4 Carcinoma, Squamous Cell 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Recurrence 2 Neoplasms 2 Mouth Neoplasms 2 Laryngeal Neoplasms 2 Glioblastoma 2 Colorectal Neoplasms 2 Carcinoma, Merkel Cell 2 Carcinoma, Large Cell 2 Carcinoma, Basal Cell 2 Carcinoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Sinonasal Squamous Cell Carcinoma 1 SMARCB1-Deficient Malignancies 1 Resectable Non-small Cell Lung Cancer 1 Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck 1

Interventions

pembrolizumab 5 Injections 4 Bevacizumab 4 Pemetrexed 3 Oxaliplatin 3 Leucovorin 3 Fluorouracil 3 Docetaxel 3 Carboplatin 3 trifluridine tipiracil drug combination 2 Paclitaxel 2 Irinotecan 2 Cetuximab 2 tislelizumab 1 sotorasib 1 palbociclib 1 olaparib 1 netrin-1 inhibitor NP137 1 fludarabine 1 cemiplimab 1 Panitumumab 1 Nivolumab 1 Itraconazole 1 HMPL-013 1 Fulvestrant 1 Etoposide 1 Drug Therapy 1 Cyclophosphamide 1 Cisplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04626635 2026-02-02

COMBINE-EGFR-1

Regeneron Pharmaceuticals

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡